MolMed gets EU patent for vascular oncology drug
Italy's MolMed has been granted a European patent on NGR-hTNF, its investigational anticancer drug targeting tumor blood vessels.
Patent no EP1255845 affords protection until 2021 with the possibility of term extension and guarantees market exclusivity in 26 European countries. In addition, the new exclusivity also covers the therapeutic candidate NGR-IFN, currently in preclinical development.
Chief executive Claudio Bordignon said: "with the grant of this new European patent specifically covering the NGR-hTNF product, along with the patents of the family previously granted in the USA and in other territories, MolMed takes a further step forward towards a strong and extended market exclusivity for NGR-hTNF: this increases indeed the value of our investigational anticancer drug, currently in Phase II clinical trials for five different types of solid tumours."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze